EUVIMEDEUVIMED entdecken
Open Access

No Smoker Left Behind: Evaluation of a Population-Based, Opt-Out Smoking Cessation Program for Patients With Cancer Who Smoke

Michael Wakeman iD, Yasmin Asvat iD, Raymond A Ruiz iD, Emma I Brett iD, Vincent Talbot, Jasmin A Tiro iD, Andrea C King iD

Journal of Clinical Oncology · 10.08.2026 · 44 (23) · 2176-2186

DOI: 10.1200/jco-25-02029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2026. Verfasst von Michael Wakeman und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Chicago, Division of the Biological Sciences, Pritzker School of Medicine, Chicago, IL. Hauptthemen laut MEDLINE: Smoking Cessation, Neoplasms, Smoking. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDA NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE We evaluated the reach, treatment selection, and effectiveness of a population-based, opt-out smoking cessation outreach program, No Smoker Left Behind, implemented in a socioeconomically and racially diverse cancer patient population. METHODS Patients seeking oncology care at the University of Chicago Comprehensive Cancer Center between 2019 and 2024 were screened for smoking status as documented in the electronic health record. Adults age 18 years and older categorized as currently smoking (past month) were systematically contacted via interactive voice response phone calls, texts, and emails for up to 6 months. They were offered several cessation treatment options, including medication and counseling referrals (ie, group program, quitline, and text message program). Program involvement and cessation outcomes were compared by cancer type (ie, smoking- or non–smoking-related) and race. A cost-outcome analysis was also conducted. RESULTS Of 37,478 patients with cancer, 3,706 (9.9%) were deemed eligible and contacted, of whom 57.0% were male, 46.6% Black, and 63.8% publicly insured. Of those selecting cessation treatments (n = 1,089), most self-selected both medication and counseling (70.6%), with 873 receiving referrals or connection to cessation support. Among patients who completed day 180 follow-up (37.5% of those receiving referrals), 16.2% (53/327) self-reported ≥8-day abstinence. Patients with smoking-related cancers had higher abstinence rates than patients with non–smoking-related cancers (23.7% v 14.7%). Black patients had higher program involvement and treatment referral rates, but significantly lower smoking abstinence compared with White patients (14.4% v 25.7%). Costs-per-patient referred to treatment were $415 US dollars (USD) and costs-per-quit were $6,067 USD. CONCLUSION Population-based, proactive opt-out outreach programs provide a feasible approach for offering multiple cessation treatment options that allow for patient preference and customization to optimize treatment accessibility. As health care systems expand access to tobacco cessation as part of cancer care, implementing resource-efficient models will become increasingly important.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smoking CessationNeoplasmsSmokingHumansMaleFemaleMiddle AgedAdultAgedCost-Benefit AnalysisCounselingProgram EvaluationReferral and Consultation

Autor:innen und Institutionen

  • University of Chicago, Division of the Biological Sciences, Pritzker School of Medicine, Chicago, IL.
  • Rush University Medical Center, Department of Psychiatry & Behavioral Sciences, Chicago, IL.
  • University of Chicago, Department of Psychiatry and Behavioral Neuroscience, Chicago, IL.
  • University of Chicago, Comprehensive Cancer Center, Chicago, IL.
  • TelASK Inc, Mount Pleasant, SC.
  • University of Chicago, Division of the Biological Sciences, Department of Public Health Sciences, Chicago, IL.

ORCID-Profile: Michael Wakeman, Yasmin Asvat, Raymond A Ruiz, Emma I Brett, Jasmin A Tiro, Andrea C King

Förderung

  • NCI NIH HHS
  • NIDA NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Wakeman, M., Asvat, Y., Ruiz, R. A., Brett, E. I., Talbot, V., Tiro, J. A., & King, A. C. (2026). No Smoker Left Behind: Evaluation of a Population-Based, Opt-Out Smoking Cessation Program for Patients With Cancer Who Smoke. Journal of Clinical Oncology, 44(23), 2176-2186. https://doi.org/10.1200/jco-25-02029

Vancouver

Wakeman M, Asvat Y, Ruiz RA, Brett EI, Talbot V, Tiro JA, et al. No Smoker Left Behind: Evaluation of a Population-Based, Opt-Out Smoking Cessation Program for Patients With Cancer Who Smoke. Journal of Clinical Oncology. 2026;44(23):2176-2186. doi:10.1200/jco-25-02029

BibTeX
@article{Wakeman2026,
  author = {Wakeman, Michael and Asvat, Yasmin and Ruiz, Raymond A and Brett, Emma I and Talbot, Vincent and Tiro, Jasmin A and King, Andrea C},
  title = {No Smoker Left Behind: Evaluation of a Population-Based, Opt-Out Smoking Cessation Program for Patients With Cancer Who Smoke},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {23},
  pages = {2176--2186},
  doi = {10.1200/jco-25-02029}
}
Kostenlos starten →